Theolytics is at the forefront of developing innovative oncolytic viral therapies aimed at transforming cancer treatment, particularly for ovarian cancer. Their approach leverages the unique properties of oncolytic viruses, which are engineered to selectively target and destroy cancer cells while also stimulating the immune system to recognize and eliminate tumors. This dual mechanism not only addresses the cancer directly but also enhances the body’s natural defenses, offering a promising avenue for patients with limited treatment options. The company’s lead program has progressed into clinical trials, reflecting their commitment to advancing therapies that could lead to lasting cures.

In addition to their primary focus on ovarian cancer, Theolytics is expanding its pipeline to include novel oncolytic virus candidates for other malignancies, such as colorectal cancer and hematological cancers. Their multidisciplinary team combines expertise in various scientific fields, including virology, cancer biology, and immunology, to drive research and development efforts. Theolytics emphasizes a culture of inclusivity and collaboration, aiming to attract top talent to support their mission of delivering transformative therapies to patients in need.

United Kingdom

Theolytics is a biotechnology company working to transform innovative therapies that represent the promise of lasting cures. The company harnesses viruses to combat cancer and is focused on developing next-generation oncolytic viral therapies.

Theolytics

Company Details